Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

carcinoma of esophagus - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

carcinoma of esophagus

MONDO:0019086

Also known as:Esophageal cancercarcinoma of the esophaguscarcinoma of the oesophagus

Find Clinical TrialsTrials

Overview

Esophageal carcinoma (EC) is a tumor arising in the epithelial cells lining the esophagus and can be divided into two subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC).

Treatments1 FDA approved

Clinical Trials443 registered · 126 recruiting

Patient Orgs1 organizations · The Arc

Diagnosis

Biomarker and diagnostic research for carcinoma of esophagus has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for carcinoma of esophagus, including PEMBROLIZUMAB (KEYTRUDA, approved 2014). An additional 4 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: 1-9 in 100,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

443 clinical trials registered, 126 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and medical devices. Pipeline includes 4 PHASE4, 27 PHASE3, 88 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05517811](https://clinicaltrials.gov/study/NCT05517811)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 6:02 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Patient Advocacy Groups

View all PAGs →

The ArcPrimary Focus

USWebsite ↗

Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.

Are you a patient organization not listed here? Claim this page to be listed and embed this content on your site — free.

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:70482

GARD

Genetic and Rare Diseases Info Center

GARD:6383

Questions for Your Care Team

→What are the benefits and potential side effects of KEYTRUDA for managing carcinoma of esophagus?
→Are any of the 443 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→How can I connect with The Arc and other patient organizations for support?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
4-Methylumbelliferone	4-Methylumbelliferone	RNR BioMedical Inc.	2020	—	Designated
Doxorubicin HCl with pluronic L-61 and pluronic F-127	Doxorubicin HCl with pluronic L-61 and pluronic F-127	Supratek Pharma Inc.	2005	—	Designated
Fluorouracil	Fluorouracil	Hoffmann-La Roche, Inc.	1989	—	Withdrawn
Interferon alfa-2a (recombinant)	Interferon alfa-2a (recombinant)	Hoffmann-La Roche, Inc.	1989	—	Withdrawn

Research Type	Count	% of Total
Research summaries	77	33%
Disease patterns and progression	38	17%
Patient case studies	27	12%
Other research	25	11%
Laboratory research	21	9%
Testing and diagnosis research	20	9%
Clinical study results	17	7%
New treatment approaches	5	2%

Kisho

carcinoma of esophagus

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

carcinoma of esophagus

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications